These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1700839)

  • 21. Acute myeloblastic leukemia.
    Molina CA; Rodríguez MJ; de Marcos NS; Font P
    Adv Ther; 2011 Mar; 28 Suppl 3():10-6. PubMed ID: 21431629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine.
    Kuendgen A; Gräf T; Zohren F; Hildebrandt B; Hünerlitürkoglu A; Gattermann N; Haas R; Kobbe G
    Leuk Res; 2007 Mar; 31(3):407-9. PubMed ID: 16890286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia.
    Lee EJ; Reck K; Schiffer CA
    Leukemia; 1990 Mar; 4(3):189-92. PubMed ID: 2314118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
    Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V; Tzouvara E; Vartholomatos G; Chaidos A; Tsiara S; Bourantas KL
    J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of acute myelogenous leukemia with outpatient azacitidine.
    Sudan N; Rossetti JM; Shadduck RK; Latsko J; Lech JA; Kaplan RB; Kennedy M; Gryn JF; Faroun Y; Lister J
    Cancer; 2006 Oct; 107(8):1839-43. PubMed ID: 16967444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Cooper BW; Veal GJ; Radivoyevitch T; Tilby MJ; Meyerson HJ; Lazarus HM; Koc ON; Creger RJ; Pearson G; Nowell GM; Gosky D; Ingalls ST; Hoppel CL; Gerson SL
    Clin Cancer Res; 2004 Oct; 10(20):6830-9. PubMed ID: 15501959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-azacytidine in acute leukemia.
    Saiki JH; McCredie KB; Vietti TJ; Hewlett JS; Morrison FS; Costanzi JJ; Stuckey WJ; Whitecar J; Hoogstraten B
    Cancer; 1978 Nov; 42(5):2111-4. PubMed ID: 82472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute lymphoblastic leukemia following preleukemic syndromes in adults.
    Escudier SM; Albitar M; Robertson LE; Andreeff M; Pierce S; Kantarjian HM
    Leukemia; 1996 Mar; 10(3):473-7. PubMed ID: 8642864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
    Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
    Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.
    van der Helm LH; Veeger NJ; Kooy Mv; Beeker A; de Weerdt O; de Groot M; Alhan C; Hoogendoorn M; Laterveer L; van de Loosdrecht AA; Koedam J; Vellenga E; Huls G
    Leuk Res; 2013 Aug; 37(8):877-82. PubMed ID: 23628552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-azacytidine in refractory acute leukemia.
    Case DC
    Oncology; 1982; 39(4):218-21. PubMed ID: 6178065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft.
    Steinmann J; Bertz H; Wäsch R; Marks R; Zeiser R; Bogatyreva L; Finke J; Lübbert M
    Bone Marrow Transplant; 2015 May; 50(5):690-5. PubMed ID: 25774594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results.
    Petti MC; Mandelli F; Zagonel V; De Gregoris C; Merola MC; Latagliata R; Gattei V; Fazi P; Monfardini S; Pinto A
    Leukemia; 1993 May; 7 Suppl 1():36-41. PubMed ID: 7683355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous infusion of 5-azacytidine as induction for acute nonlymphocytic leukemia in patients with previous exposure to 5-azacytidine.
    Gaynon PS; Baum ES
    Oncology; 1983; 40(3):192-4. PubMed ID: 6189042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.